SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $16.76 million for the quarter. SOPHiA GENETICS has set its FY 2025 guidance at EPS.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.23) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.23). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The firm had revenue of $17.73 million for the quarter, compared to the consensus estimate of $17.71 million. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
SOPHiA GENETICS Price Performance
NASDAQ:SOPH opened at $3.12 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. The company has a 50-day moving average of $3.18 and a 200-day moving average of $3.37. SOPHiA GENETICS has a 52 week low of $2.58 and a 52 week high of $6.28. The company has a market capitalization of $208.06 million, a price-to-earnings ratio of -2.86 and a beta of 1.02.
Analysts Set New Price Targets
Separately, BTIG Research set a $5.00 price objective on SOPHiA GENETICS in a report on Thursday, March 6th.
Check Out Our Latest Report on SOPHiA GENETICS
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SOPHiA GENETICS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.
While SOPHiA GENETICS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
